1P-LSD on:
[Wikipedia]
[Google]
[Amazon]
1P-LSD or 1-propionyl-lysergic acid diethylamide is a
The effects profile of 1P-LSD is not well defined in the scientific literature. It is generally thought to be comparable to that of LSD. A study in 2020 found that intravenous administration of 1P-LSD has a somewhat shorter duration than LSD in humans. 1P-LSD is present for a very short time (4 hours) prior to being completed metabolized to LSD. The 2020 study found that it is not possible to reliably distinguish between the oral uptake of LSD and 1P-LSD until unique metabolites are detected by sensitive analytical methods. Qualitative effects were similar when comparing intravenous and oral delivery between the two drugs. The slow onset after intravenous application for 1P-LSD appears to be due to the slowed passage of LSD into the
psychedelic drug
Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary states of consciousness (known as psychedelic experiences or "trips").Pollan, Michael (2018). ''How to Change Your Mind: What the New Science o ...
of the lysergamide class that is a derivative
In mathematics, the derivative of a function of a real variable measures the sensitivity to change of the function value (output value) with respect to a change in its argument (input value). Derivatives are a fundamental tool of calculus. ...
and functional analogue of LSD and a homologue of ALD-52. It has been sold online as a designer drug since 2015. It modifies the LSD molecule by adding a propionyl group to the nitrogen molecule of LSD's indole.
Pharmacology
Since LSD is detected when 1P-LSD is incubated in human serum, 1P-LSD acts, at least in part, as aprodrug
A prodrug is a medication or compound that, after intake, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug can be used to improve how the d ...
for LSD.
Effects
The effects profile of 1P-LSD is not well defined in the scientific literature. It is generally thought to be comparable to that of LSD. A study in 2020 found that intravenous administration of 1P-LSD has a somewhat shorter duration than LSD in humans. 1P-LSD is present for a very short time (4 hours) prior to being completed metabolized to LSD. The 2020 study found that it is not possible to reliably distinguish between the oral uptake of LSD and 1P-LSD until unique metabolites are detected by sensitive analytical methods. Qualitative effects were similar when comparing intravenous and oral delivery between the two drugs. The slow onset after intravenous application for 1P-LSD appears to be due to the slowed passage of LSD into the central nervous system
The central nervous system (CNS) is the part of the nervous system consisting primarily of the brain and spinal cord. The CNS is so named because the brain integrates the received information and coordinates and influences the activity of all p ...
compared to other serotonergic hallucinogens. Some users in the study reported an absence of "bad drug effects", but this is likely due to the setting than as a characteristic of 1P-LSD.
Legal status
As of 2015, 1P-LSD is not regulated under the United States Controlled Substances Act and is classified as aresearch chemical
Research chemicals are chemical substances used by scientists for medical and scientific research purposes. One characteristic of a research chemical is that it is for laboratory research use only; a research chemical is not intended for human o ...
not intended for human consumption.
1P-LSD is a controlled substance in France, Finland, Denmark, Germany, Estonia, Japan, Latvia, Norway, Romania, Sweden, Switzerland, United Kingdom, Italy, Singapore and the Czech Republic (banned in 2018).
See also
*1cP-LSD
1cP-LSD (''N''1-(cyclopropylmethanoyl)-lysergic acid diethylamide) is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug.
In tests on mice it was found to be an active psychedelic with similar pote ...
* 1B-LSD
1B-LSD (N1-butyryl-lysergic acid diethylamide) is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug. In tests on mice it was found to be an active psychedelic, though with only around 1/7 the poten ...
* 1V-LSD
* ALD-52
* 1cP-AL-LAD
* AL-LAD
* ETH-LAD
* 1P-ETH-LAD
1P-ETH-LAD (1-propionyl-6-ethyl-6-nor-lysergic acid diethylamide) is an analog of LSD. 1P-ETH-LAD is a psychedelic drug similar to LSD. Research has shown formation of ETH-LAD from 1P-ETH-LAD incubated in human serum, suggesting that it functions ...
* PRO-LAD
PRO-LAD is an analogue of LSD. It is described by Alexander Shulgin in the book TiHKAL. PRO-LAD is a psychedelic drug similar to LSD, and is around as potent as LSD itself with an active dose reported at between 100 and 200 micrograms.
Legal st ...
* LSM-775
* LSZ
Lysergic acid 2,4-dimethylazetidide (LA-SS-Az, LSZ) is an analog of LSD developed by the team led by David E. Nichols at Purdue University. It was developed as a rigid analog of LSD with the diethylamide group constrained into an azetidine r ...
* O-Acetylpsilocin (4-AcO-DMT)
References
{{Ergolines Designer drugs Lysergamides Prodrugs Serotonin receptor agonists